Patents Assigned to Novo Nordisk A/S
  • Patent number: 11980742
    Abstract: A device for administering a fluid medicament by injection comprises a dosing portion (1) with a collapsible reservoir (10). The reservoir (10) has a maximum volume in an extended state and a minimum volume in a collapsed state. Prior to injection, the reservoir (10) is in the extended state and contains a liquid to be administered, and the reservoir (10) is biased towards the collapsed state. The device further comprises a needle (2), wherein a lumen (20) of the needle (2) is in fluid communication with the reservoir (10). The device further comprises a shield portion (3) with a plug (30). Prior to injection, the shield portion (3) is in a deployed position where the plug (30) blocks the lumen (20) of the needle (2). The shield portion (3) is adapted to move in response to an actuation force from the deployed position to a retracted position where the lumen (20) of the needle (2) is open, thereby causing the reservoir (10) to shift to the collapsed state to expel the liquid through the needle.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 14, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Schau Andersen, Simon Roervig, Steffen Hansen
  • Publication number: 20240123159
    Abstract: 1. A drug delivery device for delivering a plurality of fixed doses of a medicament, wherein the drug delivery device comprises a needle magazine with a plurality of needle assemblies, a needle positioning mechanism, a drive mechanism for delivering a fixed dose of the plurality of fixed doses, in response to activation, an activation mechanism for activating the drive mechanism comprising a movable shield (110, 310), wherein the shield (110, 310) is adapted to activate the drive mechanism, in response moving the shield to the proximal position. The drug delivery device further comprises a drop lock mechanism comprising a non-blocking state and a blocking state.
    Type: Application
    Filed: February 15, 2022
    Publication date: April 18, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Bo Kvolsbjerg, Nicolai Michael Villadsen
  • Patent number: 11952574
    Abstract: Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: April 9, 2024
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Anna Linda Blois, Christina Marie Priest, Jihye Park, Henryk Dudek
  • Patent number: 11944791
    Abstract: A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion (310) and a single-use flow conducting device (360) adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path (304) different from an unintended flow path (303).
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: April 2, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Bengtsson, Vera Pinto Glenting, Joern Drustrup, Jonas Kildegaard Pedersen
  • Patent number: 11931556
    Abstract: The present invention provides a drug injection device (100, 100?, 100?) comprising a first element (130) and a second element (102, 102?, 102?) configured to undergo movement relative to each other corresponding to an action performed on or by the drug injection device (100, 100?, 100?), wherein the first element (130) comprises serially disposed protrusions (133), and wherein the second element (102, 102?, 102?) comprises a second element base and a deflectable transducer (170, 170?, 170?). The deflectable transducer (170, 170?, 170?) defines a base portion attached to the second element base, and a deflectable portion (162) configured for sequentially cooperating with the plurality of protrusions (133), wherein a processor (165) is electrically connected with the deflectable transducer (170, 170?, 170?) to register activation signals.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: March 19, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Nikolaj Eusebius Jakobsen, Per Einar Pontus Holm
  • Publication number: 20240066235
    Abstract: The invention relates to a medical injection device for dispensing substantially equally sized dose volumes of a liquid drug. The injection is driven by a torsion spring which is strained prior to each dose release by rotation of a connector element connecting the torsion spring to the rotational drive structure. The dose release is controlled by an axial movement of the rotational drive structure which can only be moved axially when the connector element has been rotated to a specific rotational position.
    Type: Application
    Filed: January 14, 2022
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventor: Nikolaj Eusebius Jakobsen
  • Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • Patent number: 11912759
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: February 27, 2024
    Assignees: NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORK
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Publication number: 20240016896
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: July 26, 2023
    Publication date: January 18, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • Patent number: 11873332
    Abstract: The invention provides antibody formulations and methods useful for prophylaxis or treatment of transthyretin-related amyloidosis.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: January 16, 2024
    Assignee: NOVO NORDISK A/S
    Inventors: Joseph Alexander Soto, Andrea Hawe, Ruedeeporn Tantipolphan, Stefan Heindl
  • Patent number: 11858992
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: January 2, 2024
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Patent number: 11840560
    Abstract: Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: December 12, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Patrick James Knerr, Brian Patrick Finan
  • Patent number: 11833248
    Abstract: The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: December 5, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Betty Lomstein Pedersen, Birgitte Nissen
  • Patent number: 11787837
    Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 17, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Kim Birkebaek Jensen, Magnus Bernt Fredrik Gustafsson
  • Patent number: 11787874
    Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 17, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
  • Patent number: 11779648
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: October 10, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Patrick James Knerr, Brian Finan, Richard Dimarchi
  • Patent number: 11780910
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: October 10, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • Patent number: 11771829
    Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject) such as a liquid pharmaceutical agent.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 3, 2023
    Assignees: Massachusetts Institute of Technology, Novo Nordisk A/S, The Brigham and Women's Hospital, Inc.
    Inventors: Robert S. Langer, Carlo Giovanni Traverso, Alex G. Abramson, Morten Revsgaard Frederiksen, Mikkel Oliver Jespersen, Brian Mouridsen, Jesper Windum, Mette Poulsen, Brian Jensen, Jorrit Jeroen Water, Mikkel Wennemoes Hvitfeld Ley, Xiaoya Lu, Andreas Vegge
  • Publication number: 20230302094
    Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
    Type: Application
    Filed: June 12, 2023
    Publication date: September 28, 2023
    Applicant: Novo Nordisk A/S
    Inventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher
  • Patent number: 11767332
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: September 26, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova